Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from July 12-13.
Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on July 13.
A webcast of the event will be available here beginning at 9am ET on July 11 and posted on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
CONTACTS:
Investors and Media:
Meg Dodge
Krystal Biotech
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$149.74 |
| Daily Change: | 0.68 0.46 |
| Daily Volume: | 241,741 |
| Market Cap: | US$4.330B |
July 09, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
